Can Ozempic or Wegovy Help You Quit Smoking?

Maybe, but nobody has proven it yet. Ozempic and Wegovy (semaglutide) are not approved to help you quit smoking, and a small randomized trial in people who smoke found that semaglutide cut cravings and body weight without clearly cutting cigarettes (2).

The better-supported tools are still varenicline, nicotine replacement and a free quitline, and those are the ones with FDA approval for this use (11). Where a GLP-1 might earn a place is with the weight people gain after they quit, and that question is being tested right now.

Why anyone thinks a diabetes drug would touch nicotine

Patients started telling clinicians that something odd happened on these drugs. They wanted fewer drinks and fewer cigarettes (1). The drugs act on reward circuits as well as appetite, and animal work backs that up, which is why researchers took the reports seriously instead of filing them under anecdote (6).

Reports are a starting point, though. They are not evidence of benefit. So what has actually been measured?

The big electronic health record study

The paper everyone cites is Wang and colleagues, published in Annals of Internal Medicine in 2024 (1). They used a national database of health records and emulated seven trials in people with both type 2 diabetes and a tobacco use disorder diagnosis, comparing new semaglutide users with new users of other diabetes drugs. The analysis covered 222,942 people, 5,967 of them starting semaglutide.

Over 12 months, semaglutide users had fewer medical encounters for tobacco use disorder than people on insulin (hazard ratio 0.68, 95 percent CI 0.63 to 0.74) and fewer than people on other GLP-1 drugs (0.88, CI 0.81 to 0.96). They also had fewer prescriptions for cessation medication and less cessation counseling. Most of the gap showed up within 30 days of starting the drug (1).

Read that last part twice. The study measured health care use, not whether anyone stopped smoking. Fewer cessation prescriptions could mean people needed them less. It could also mean something else entirely, such as sicker patients being channeled to other drugs, or differences in how visits were coded. The authors listed documentation bias, residual confounding, and missing data on actual smoking, weight and adherence as limits, and they asked for trials (1). I agree with that ask. A hazard ratio built on billing codes cannot tell you that a drug helps a person quit.

What randomized trials show

Here the picture gets less exciting.

The strongest signal for any GLP-1 drug is a small pilot with extended-release exenatide. Researchers randomized 84 smokers with prediabetes or overweight to exenatide 2 mg weekly or placebo, and everyone wore a 21 mg nicotine patch. At the end of six weeks, 46.3 percent of the exenatide group were abstinent against 26.8 percent on placebo. The confidence interval was wide (risk ratio 1.70, credible interval 0.96 to 3.27), and the exenatide group weighed 5.6 pounds less (3). A larger exenatide trial of 216 people has been designed, but published results were not available at the time of writing (8).

Then came dulaglutide, tested in Basel on 255 people who were already getting varenicline and counseling. At 12 weeks the groups looked the same, 63 percent abstinent on dulaglutide and 65 percent on placebo. At 52 weeks it was 32 percent in both arms (4). No help with quitting at all.

Semaglutide has one randomized trial in smokers, a phase 2a study published in JAMA Network Open in 2026 (2). It enrolled 45 people and randomized 24 adults who smoked at least five cigarettes a day and were not trying to quit, giving them semaglutide up to 1.0 mg or placebo for nine weeks. The two primary laboratory measures of smoking were not significant. Craving fell significantly, and body weight dropped about 5 percent while the placebo group gained about 1.6 percent. Cigarettes per day fell in both groups with no real difference between them (2). Twelve people per arm is a pilot, and nobody in it was attempting to quit.

One more small piece. A 2025 trial of semaglutide in 48 adults with alcohol use disorder, which I will mention only because it is the same hypothesis, found less craving and less drinking per drinking day. In the few participants who smoked, cigarettes per day dropped more on semaglutide than placebo (9). That is a subgroup of a secondary outcome. I would not build a plan on it.

A 2026 systematic review pulling this together reached a sensible conclusion: exenatide looked best, dulaglutide did not improve abstinence, and semaglutide had mostly observational support. It asked for larger, better-designed trials (6).

The weight gain problem is real

This is where I think the idea has the most promise, so I want to spend a minute on it.

People who quit smoking gain weight. In a meta-analysis of 62 studies, untreated quitters gained an average of 4.67 kg (about 10 pounds) at 12 months, most of it within the first three months. About 16 percent lost weight, and 13 percent gained more than 10 kg. Using varenicline, bupropion or nicotine replacement did not change that much (13). For many patients, particularly those who already carry excess weight, fear of that gain is a reason not to try.

The Basel trial shows both the hope and the catch. At 12 weeks, dulaglutide held weight at minus 1.0 kg while placebo gained 1.9 kg. After the injections stopped, the difference faded, and by week 52 the groups sat at about 2.8 and 3.1 kg above baseline (4). A follow-up analysis from the same trial found blood pressure rose again as the weight came back (5). If a GLP-1 is going to blunt post-quit weight gain, the effect likely lasts only as long as the drug does.

A trial built for this exact question is underway. It will randomize 177 smokers with obesity or overweight to semaglutide 2.4 mg or placebo for 28 weeks, with nicotine patches and counseling for everyone. Its primary outcome is weight change. Quit rates are only an exploratory outcome (7).

I screen for nicotine at every initial visit. I ask whether the patient smokes or vapes, and whether they want to quit. I’ll be honest that I haven’t made a habit of going back later to ask whether the medication changed their desire to smoke or vape. It is a good follow-up question, and it is one I plan to start asking.

What actually works for quitting

The comparison that matters is against treatments with real proof. A 2023 Cochrane network meta-analysis of 319 trials with more than 157,000 participants found that varenicline roughly doubled the odds of quitting (OR 2.33), which works out to about eight more quitters per 100 people treated. Nicotine e-cigarettes and cytisine looked similar. Combination nicotine replacement, a patch plus a fast-acting form like gum or lozenge, had an OR of 1.93. Patch alone (1.37) and bupropion (1.43) helped, with two to three extra quitters per 100 (10).

The US Preventive Services Task Force gives a grade A recommendation to behavioral support plus FDA-approved medication for adults who smoke, and names nicotine replacement, bupropion SR and varenicline (11). Counseling does not have to happen in an office. 1-800-QUIT-NOW connects you to your state quitline, it is free and confidential (12).

When someone wants to quit and has never taken a weight loss medication, we talk about naltrexone with bupropion. That combination is approved for weight management, and the bupropion in it may also lower the urge to keep smoking. Bupropion on its own is one of the FDA-approved quit-smoking medications (11). Using a GLP-1 together with naltrexone and bupropion is also a possibility for some people. Whether it makes sense depends on their health history and what is safe for them, including the other medications they take and possible drug interactions.

Should you ask for Ozempic to quit smoking?

No, not for that reason alone. If your weight, blood sugar or cardiovascular risk meets the criteria for a GLP-1, that is a legitimate conversation, and some patients will notice less interest in cigarettes along the way. But using a prescription medication for an indication it has not been shown to treat means paying for it, accepting its side effects, and skipping drugs that do work.

I tell them the truth: a GLP-1 isn’t approved for that right now. Then we talk about whether there are other reasons they might want the medication. If they also have overweight or obesity, we can go over the treatment options, including naltrexone with bupropion, either as the two separate generics or as the brand-name combination.

If you smoke and want to quit now, do not wait for a GLP-1 trial to report. Pick a proven drug, call the quitline, and set a quit date.

For patients and for clinicians

If you smoke

Start with varenicline or combination nicotine replacement and a quitline. If you are already on a GLP-1 for weight or diabetes, tell whoever is prescribing your quit medication so they see the whole picture. Expect some weight gain after quitting and plan for it up front rather than treating it as a reason to keep smoking. In my view the weight is the smaller problem.

If you prescribe

Ask about tobacco at every GLP-1 visit and document it. Offer a proven cessation drug first and consider the GLP-1 as a separate decision on its own indication. I would call the Wang cohort hypothesis-generating at best (1), the semaglutide RCT too small to change practice (2), and the weight-gain trial the one to watch (7). Counsel that any weight effect may fade if the GLP-1 stops (4).

The Bottom Line

Ozempic and Wegovy are not approved for quitting smoking, and the evidence is mixed. Health record data link semaglutide to fewer tobacco-related visits, but the one small semaglutide trial in smokers showed lower craving and weight, not a clear drop in smoking, and dulaglutide did not help people quit at all.

The real opening may be the weight people gain after quitting, and a semaglutide trial for exactly that is running. Until it reports, use what has been proven, which is varenicline or combination nicotine replacement, plus counseling through 1-800-QUIT-NOW.

Related Reading

Food Addiction and Obesity: How the Brain Is Involved
Is Obesity a Brain Problem? How the Body Controls Weight
Weight Loss Drug Side Effects and How Common They Are
Which Medications Can Make Weight Loss Harder?
Wegovy and Zepbound Cash Pay Prices Without Insurance (2026 Update)
More on Weight Loss & Metabolic Health

Scott Rennie, DO, DABOM
Board Certified in Obesity Medicine and Family Medicine
Menopause training through The Menopause Society
LinkedIn · Doximity

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

  1. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data. Ann Intern Med. 2024;177(8):1016-1027. https://pubmed.ncbi.nlm.nih.gov/39074369/
  2. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2614898. https://pmc.ncbi.nlm.nih.gov/articles/PMC13213524/
  3. Yammine L, Green CE, Kosten TR, et al. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021;23(10):1682-1690. https://pmc.ncbi.nlm.nih.gov/articles/PMC8517504/
  4. Lüthi H, Lengsfeld S, Burkard T, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2024;68:102429. https://pmc.ncbi.nlm.nih.gov/articles/PMC10873660/
  5. Beck J, Hasenböhler F, Werlen L, et al. Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment. Eur J Prev Cardiol. 2025;32(14):1394-1402. https://pubmed.ncbi.nlm.nih.gov/40037282/
  6. Bhaduri G, Mukherjee S, Parikh R, Karak S, Pal J. GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia. Endocrine. 2026;91(1):82. https://pubmed.ncbi.nlm.nih.gov/41697556/
  7. Yammine L, Leidy H, Maki KC, et al. A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. Contemp Clin Trials. 2025;155:107989. https://pubmed.ncbi.nlm.nih.gov/40554081/
  8. Yammine L, Verrico CD, Versace F, et al. Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial. BMJ Open. 2023;13(6):e072707. https://pmc.ncbi.nlm.nih.gov/articles/PMC10277057/
  9. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/
  10. Lindson N, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023. https://pubmed.ncbi.nlm.nih.gov/37696529/
  11. US Preventive Services Task Force. Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions. January 19, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
  12. CDC. Quitlines and Other Cessation Support Resources. https://www.cdc.gov/tobacco/hcp/patient-care/quitlines-and-other-resources.html
  13. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012;345:e4439. https://pmc.ncbi.nlm.nih.gov/articles/PMC3393785/

Discover more from Dr. Scott Rennie

Subscribe to get the latest posts sent to your email.

Leave a Reply